ELF

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Retrieved on: 
Thursday, March 7, 2024

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced publication of results in Clinical Gastroenterology and Hepatology from an expansion cohort (Cohort D, N=31) of the Phase 2b SYMMETRY study.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced publication of results in Clinical Gastroenterology and Hepatology from an expansion cohort (Cohort D, N=31) of the Phase 2b SYMMETRY study.
  • Tolerability of EFX on top of GLP-1RA (N=21 patients) was generally comparable to GLP-1RA alone (placebo, N=10).
  • The most frequent adverse events for EFX-treated patients were grade 1 or 2 gastrointestinal events (diarrhea, nausea, and increased appetite).
  • Patients treated with EFX plus GLP-1RA showed a similar mean weight loss from baseline relative to patients treated with GLP-1RA alone.

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.
  • Positive safety and efficacy data from 320 mg dose cohort of INTEGRIS-PSC Phase 2a trial in patients with primary sclerosing cholangitis (PSC).
  • At a once-daily dose of 320 mg, bexotegrast was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events.
  • The increase was due to higher operating expenses coupled with a decrease in collaboration revenues under the Novartis collaboration during the quarter.

OKX's 16th Consecutive Proof of Reserves Report: USD17.7 Billion in Primary Assets

Retrieved on: 
Monday, February 26, 2024

DUBAI, UAE, Feb. 26, 2024 /PRNewswire/ -- OKX , a leading global Web3 technology company and crypto exchange, today announced the release of its 16th consecutive Proof of Reserves (PoR) report, highlighting a total of USD17.7 billion and an average reserve ratio of 104% in primary assets.

Key Points: 
  • DUBAI, UAE, Feb. 26, 2024 /PRNewswire/ -- OKX , a leading global Web3 technology company and crypto exchange, today announced the release of its 16th consecutive Proof of Reserves (PoR) report, highlighting a total of USD17.7 billion and an average reserve ratio of 104% in primary assets.
  • OKX included Bitcoin Cash (BCH) in its PoR report for the first time in January 2024.
  • Reiterating the consistency of previous reports, OKX's 16th consecutive monthly PoR report reveals reserve ratios of over 100% for all of these assets, thereby ensuring that user funds are backed on a 1:1 basis.
  • Since the inception of the program, OKX has integrated various updates and improvements to its PoR based on user feedback.

OKX's 16th Consecutive Proof of Reserves Report: USD17.7 Billion in Primary Assets

Retrieved on: 
Monday, February 26, 2024

DUBAI, UAE, Feb. 26, 2024 /PRNewswire/ -- OKX , a leading global Web3 technology company and crypto exchange, today announced the release of its 16th consecutive Proof of Reserves (PoR) report, highlighting a total of USD17.7 billion and an average reserve ratio of 104% in primary assets.

Key Points: 
  • DUBAI, UAE, Feb. 26, 2024 /PRNewswire/ -- OKX , a leading global Web3 technology company and crypto exchange, today announced the release of its 16th consecutive Proof of Reserves (PoR) report, highlighting a total of USD17.7 billion and an average reserve ratio of 104% in primary assets.
  • OKX included Bitcoin Cash (BCH) in its PoR report for the first time in January 2024.
  • Reiterating the consistency of previous reports, OKX's 16th consecutive monthly PoR report reveals reserve ratios of over 100% for all of these assets, thereby ensuring that user funds are backed on a 1:1 basis.
  • Since the inception of the program, OKX has integrated various updates and improvements to its PoR based on user feedback.

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Retrieved on: 
Sunday, February 4, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. There was no dose relationship for adverse events. Pruritus and cholangitis occurred less frequently on bexotegrast than on placebo.

Key Points: 
  • The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging (MRI) of the liver.
  • In addition, MRI imaging continued to show evidence of improved hepatocyte function and bile flow with bexotegrast at the 320 mg dose relative to placebo.
  • INTEGRIS-PSC is a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a trial evaluating bexotegrast at once-daily oral doses of 40 mg, 80 mg, 160 mg, 320 mg or placebo for 12 weeks in 121 patients with PSC.
  • The 320 mg group enrolled 27 patients in the active arm and added 9 new patients to the pooled placebo arm.

OKX's 15th Consecutive Proof of Reserves Report: USD14.9 Billion in Primary Assets, Including Bitcoin Cash For First Time

Retrieved on: 
Wednesday, January 31, 2024

As with its previous reports, OKX's 15th consecutive monthly PoR reveals reserve ratios of over 100% for all of these assets.

Key Points: 
  • As with its previous reports, OKX's 15th consecutive monthly PoR reveals reserve ratios of over 100% for all of these assets.
  • The current reserve ratios for OKX's primary assets are as follows:
    OKX Global Chief Commercial Officer Lennix Lai said: "Our Proof of Reserves program stands as a symbol of transparency and trust in the industry.
  • We remain steadfast in our commitment to regularly publish monthly reports, incorporate user feedback and adopt industry best practices.
  • In October 2023, OKX marked the one-year anniversary of its PoR program with a video advocating for Proof of Reserves as an industry standard.

OKX's 15th Consecutive Proof of Reserves Report: USD14.9 Billion in Primary Assets, Including Bitcoin Cash For First Time

Retrieved on: 
Wednesday, January 31, 2024

As with its previous reports, OKX's 15th consecutive monthly PoR reveals reserve ratios of over 100% for all of these assets.

Key Points: 
  • As with its previous reports, OKX's 15th consecutive monthly PoR reveals reserve ratios of over 100% for all of these assets.
  • The current reserve ratios for OKX's primary assets are as follows:
    OKX Global Chief Commercial Officer Lennix Lai said: "Our Proof of Reserves program stands as a symbol of transparency and trust in the industry.
  • We remain steadfast in our commitment to regularly publish monthly reports, incorporate user feedback and adopt industry best practices.
  • In October 2023, OKX marked the one-year anniversary of its PoR program with a video advocating for Proof of Reserves as an industry standard.

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Retrieved on: 
Tuesday, January 9, 2024

NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.

Key Points: 
  • NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.
  • Recent landmark genetic research confirmed the link between this rare, devastating condition experienced during pregnancy to higher levels of GDF15.
  • Given our deep expertise in GDF15 biology, we believe we are well positioned to potentially pursue this indication for NGM120.
  • NGM Bio previously reported data from a randomized, double-blind, placebo-controlled Phase 2 study of aldafermin for the treatment of PSC.

Edison issues update on Deutsche Beteiligungs (DBAN): Solid exits in FY23, expanding into private debt

Retrieved on: 
Thursday, December 21, 2023

Edison issues update on Deutsche Beteiligungs (DBAN): Solid exits in FY23, expanding into private debt

Key Points: 
  • Edison issues update on Deutsche Beteiligungs (DBAN): Solid exits in FY23, expanding into private debt
    The issuer is solely responsible for the content of this announcement.
  • Edison issues update on Deutsche Beteiligungs (DBAN): Solid exits in FY23, expanding into private debt
    Deutsche Beteiligungs (DBAG) posted a strong 18.1% NAV TR in FY23 (to end-September 2023), which more than offset the NAV TR loss in FY22 of c 13%.
  • Moreover, DBAG’s management decided to enter the fast-growing private debt market through the acquisition of a majority stake in ELF Capital, with DBAG making a €100m investment commitment to ELF Capital’s funds.
  • This may appeal to investors seeking exposure to cyclical value companies in anticipation of a potential rebound in the German economy.

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

Retrieved on: 
Monday, November 13, 2023

EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”; previously referred to as “NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced additional efficacy data for rencofilstat, its lead drug candidate.

Key Points: 
  • Dr. Mayo’s presentation indicated that 17 weeks of rencofilstat treatment was associated with significant reduction in liver stiffness (FibroScan®) in MASH subjects with advanced F3, an outcome suggesting reduction in hepatic fibro-inflammation.
  • Ongoing hepatic fibro-inflammation leads to progressive accumulation of collagen or fibrosis, increasing liver stiffness, and functional deterioration.
  • The predictive power of liver stiffness measurements on the course of disease is further enhanced when taken together with blood-based markers of liver disease.
  • Reduction in liver stiffness by rencofilstat likely indicates reduction in fibroinflammation, and reduction in risk for subsequent clinical outcome.